190 related articles for article (PubMed ID: 19819114)
21. Interpreting treatment trials in schizophrenia patients: lessons learned from EUFEST.
Fleischhacker WW; Derks E; Kahn RS
Schizophr Res; 2012 Jun; 138(1):39-40. PubMed ID: 22542244
[TBL] [Abstract][Full Text] [Related]
22. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Soares-Weiser K; Béchard-Evans L; Lawson AH; Davis J; Ascher-Svanum H
Eur Neuropsychopharmacol; 2013 Feb; 23(2):118-25. PubMed ID: 22633617
[TBL] [Abstract][Full Text] [Related]
23. Olanzapine and haloperidol in first episode psychosis: two-year data.
Green AI; Lieberman JA; Hamer RM; Glick ID; Gur RE; Kahn RS; McEvoy JP; Perkins DO; Rothschild AJ; Sharma T; Tohen MF; Woolson S; Zipursky RB;
Schizophr Res; 2006 Sep; 86(1-3):234-43. PubMed ID: 16887334
[TBL] [Abstract][Full Text] [Related]
24. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
Stahl SM; Malla A; Newcomer JW; Potkin SG; Weiden PJ; Harvey PD; Loebel A; Watsky E; Siu CO; Romano S
J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437
[TBL] [Abstract][Full Text] [Related]
25. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
26. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.
Fleischhacker WW; Siu CO; Bodén R; Pappadopulos E; Karayal ON; Kahn RS;
Int J Neuropsychopharmacol; 2013 Jun; 16(5):987-95. PubMed ID: 23253821
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
[TBL] [Abstract][Full Text] [Related]
29. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.
Perkins D; Lieberman J; Gu H; Tohen M; McEvoy J; Green A; Zipursky R; Strakowski S; Sharma T; Kahn R; Gur R; Tollefson G;
Br J Psychiatry; 2004 Jul; 185():18-24. PubMed ID: 15231551
[TBL] [Abstract][Full Text] [Related]
30. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
[TBL] [Abstract][Full Text] [Related]
31. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
[TBL] [Abstract][Full Text] [Related]
32. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
33. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis.
Beasley CM; Stauffer VL; Liu-Seifert H; Taylor CC; Dunayevich E; Davis JM
J Clin Psychopharmacol; 2007 Jun; 27(3):252-8. PubMed ID: 17502771
[TBL] [Abstract][Full Text] [Related]
34. Time to Discontinuation of Second-Generation Antipsychotics Versus Haloperidol and Sulpiride in People With Schizophrenia: A Naturalistic, Comparative Study.
Chan HY; Pan YJ; Chen JJ; Chen CH
J Clin Psychopharmacol; 2017 Feb; 37(1):13-20. PubMed ID: 27977467
[TBL] [Abstract][Full Text] [Related]
35. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ortiz-Garcia de la Foz V; Martínez-Garcia O; Valdizan EM; Vazquez-Barquero JL
J Clin Psychopharmacol; 2013 Apr; 33(2):215-20. PubMed ID: 23422371
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis.
Zhang JP; Gallego JA; Robinson DG; Malhotra AK; Kane JM; Correll CU
Int J Neuropsychopharmacol; 2013 Jul; 16(6):1205-18. PubMed ID: 23199972
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
[TBL] [Abstract][Full Text] [Related]
38. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses.
Hugenholtz GW; Heerdink ER; Stolker JJ; Meijer WE; Egberts AC; Nolen WA
J Clin Psychiatry; 2006 Jun; 67(6):897-903. PubMed ID: 16848649
[TBL] [Abstract][Full Text] [Related]
39. Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia.
Gaebel W; Riesbeck M; Wölwer W; Klimke A; Eickhoff M; von Wilmsdorff M; Heuser I; Maier W; Klosterkötter J; Falkai P; Schlösser R; Schmitt A; Riedel M; Klingberg S; Köpcke W; Ohmann C; Möller HJ
Schizophr Res; 2014 Feb; 152(2-3):478-86. PubMed ID: 23643327
[TBL] [Abstract][Full Text] [Related]
40. The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine.
Rasmussen SA; Rosebush PI; Anglin RE; Mazurek MF
Psychiatry Res; 2016 Jul; 241():72-7. PubMed ID: 27156027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
